Bruno Dubois
Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris, University Pierre et Marie Curie Paris VI. He is Director of the Behavioural Neurology Department and of the Dementia Research Center at the Hospital. He is also Director of the Research Unit Inserm U-610 of the ICM (Institut du Cerveau et de la Moelle Epinière) of the Hospital. He is coordinator of the National Reference Center on Rare Dementias and of the National Reference Center for young-onset Alzheimer patients. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (EADC). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacology; an
AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease Paris Stock Exchange:AB
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
AB SCIENCE WILL HOST A LIVE WEBCAST ON THURSDAY DECEMBER 17, 2020 ON MASITINIB RESULTS IN ALZHEIMER’S DISEASE
Paris, December 16, 2020, 6pm CET
AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.
The webcast will feature presentations by four Key Opinion Leaders:
Bruno Dubois, MD (Neurological Institute of the Salpêtrière University Hospital, Paris)
Philip Scheltens, MD, PhD (Alzheimer Center at the VU University Medical Center, Amsterdam)
Jeffrey L. Cummings, MD (Chamber-Grundy Center for Transformative Neuroscience at UNLV, Las Vegas)